Diet and benign prostatic hyperplasia: Implications for prevention

Urology

Volumn 68, Issue 3, 2006, Pages 470-476

  Ranjan, Priyadarshi ^a   Dalela, Diwakar ^a   Sankhwar, Satya Narayan ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALCOHOL; APIGENIN; BXL 628; FLAVONOID; GLUTAMIC ACID; GLYCINE; KAEMPFEROL; LIGNAN; LIPID; LYCOPENE; PHYTOESTROGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ALCOHOL CONSUMPTION; ANIMAL PRODUCT; COFFEE; DIET; DIETARY INTAKE; ESTROGEN ACTIVITY; FRUIT; HISTOLOGY; HUMAN; LINSEED; MILK; MORTALITY; NUTRITIONAL ASSESSMENT; PLANT PRODUCT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SOYBEAN; TEA; TOMATO; VEGETARIAN DIET;

DIET; HUMANS; MALE; PHYTOESTROGENS; PROSTATIC HYPERPLASIA;

EID: 33748925210     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.04.023     Document Type: Review

References (50)

1. Srivastava A.R., and Dalela D. Prostate cancer: altering the natural history by dietary changes. Natl Med J India 17 (2004) 248-253
2. Suzuki S., Platz E.A., Kawachi I., et al. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75 (2002) 689-697
3. Heber D. Prostate enlargement: the canary in the coal mine?. Am J Clin Nutr 75 (2002) 605-606
4. Araki H., Watanabe H., Mishina T., et al. High risk group for benign prostatic hypertrophy. Prostate 4 (1983) 253-264
5. Moon T.D., Brannan W., Stone N.N., et al. Effect of age, educational status, ethnicity and geographical location on prostate symptom scores. J Urol 152 (1994) 1498-1500
6. Denis L., Morton M.S., and Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 35 (1999) 377-387
7. Garraway W.M., and Alexander F.E. Prostate disease: epidemiology, natural history and demographic shifts. Br J Urol 79 (1997) 3-8
8. Isaacs J.T., and Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2 (1989) 33-50
9. Andriole G., Bruchovsky N., Chung L.W., et al. Dihydrotestosterone and the prostate: the scientific rationale for 5 alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172 (2004) 1399-1403
10. Donald J.T., Charles Y., Young F., et al. Role of androgens and nutritional factors in prostate development and function. J Nutr 131 (2001) 186S
11. Weihua Z., Makela S., Andersson L.C., et al. A role for oestrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci 98 (2001) 6330-6335
12. Vij U., and Kumar A. Phytoestrogens and prostatic growth. Natl Med J India 17 (2004) 22-26
13. Morton M.S., Chan P.S., Cheng C., et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong and the United Kingdom. Prostate 32 (1997) 122-128
14. Messina M.J., Persky V., Setchell K.R., et al. Soy intake and cancer risk: a review of in vitro and in vivo data. Nutr Cancer 21 (1994) 113-131
15. Geller J., Sionit L., Partido C., et al. Genistein inhibits the growth of human-patient benign prostatic hyperplasia and prostate cancer in histoculture. Prostate 34 (1998) 75-79
16. Roberts R.O., Jacobson D.J., Rhodes T., et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61 (2004) 124-131
17. Nagata C., Inaba S., Kawakami N., et al. Inverse association of soy product intake with serum androgen and oestrogen concentrations in Japanese men. Nutr Cancer 36 (2000) 14-18
18. Sciarra F., and Toscano V. Role of oestrogens in human benign prostatic hyperplasia. Arch Androl 44 (2000) 213-220
19. Tan M.O., Karabiyik I., Uygur M.C., et al. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia. Int Urol Nephrol 35 (2003) 357-363
20. Yi M.A., Son H.M., Lee J.S., et al. Regulation of male sex hormone levels by soy isoflavones in rats. Nutr Cancer 42 (2002) 206-210
21. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha reductase and 17 beta hydroxysteroid dehydrogenase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147 (1995) 295-302
22. Bravi F., Bosetti C., Dal Maso L., et al. Food groups and risk of benign prostatic hyperplasia. Urology 67 (2006) 73-79
23. Lagiou P., Wuu J., Trichopoulou A., et al. Diet and benign prostatic hyperplasia: a study in Greece. Urology 54 (1999) 284-290
24. Bosetti C., Micelotta S., Dal Maso L., et al. Food groups and risk of prostate cancer in Italy. Int J Cancer 110 (2004) 424-428
25. Obermuller-Jevic U.C., Olano-Martin E., Corbacho A.M., et al. Lycopene inhibits growth of normal human prostate epithelial cells in vitro. J Nutr 133 (2003) 3356-3360
26. Wertz K., Siler U., and Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430 (2004) 127-134
27. Kim H.S., Bowen P., Chen L., et al. Effects of tomato sauce on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer 47 (2003) 40-47
28. Lin X., Gingrich J.R., Bao W., et al. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 60 (2002) 919-924
29. Knight D.C., and Eden J.A. A review of the clinical effects of phyto-oestrogens. Obstet Gynecol 87 (1996) 897-904
30. Denmark W., Robertson C.N., Walther P.J., et al. Pilot study to explore effects of low fat and flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate specific antigen. Urology 63 (2004) 900-904
31. Neuhouser M.L., Kristal A.R., and Penson D.F. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors benign prostatic hyperplasia: a review of epidemiologic literature. Urology 64 (2004) 201-211
32. Soygur T., Kupeli B., Aydos K., et al. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 28 (1996) 55-59
33. Weisser H., Ziemssen T., and Kreig M. Phospholipase A2 degradation products modulate epithelial and stromal 5 alpha reductase activity of human benign prostatic hyperplasia in vitro. Prostate 50 (2002) 4-14
34. Meigs J.B., Mohr B., Barry M.J., et al. Risk factors for clinical benign prostatic hyperplasia in a community based population of healthy ageing men. J Clin Epidemiol 54 (2001) 935-944
35. Jonas A., Rosenblat G., Krapf D., et al. Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5 alpha reductase activity, aromatase activity and lipid peroxidation. Urol Res 26 (1998) 265-270
36. Chyou P.H., Nomura A.M., Stemmermann G.N., et al. A prospective study of alcohol, diet and other lifestyle factors in relation to obstructive uropathy. Prostate 22 (1993) 253-264
37. Koskimaki J., Hakama M., Huhtala H., et al. Association of dietary elements and lower urinary tract symptoms. Scand J Urol Nephrol 34 (2000) 46-50
38. Liao S., and Hiipakka R.A. Selective inhibition of steroid 5 alpha reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 214 (1995) 833-838
39. Liao S. The medical action of androgens and green tea epigallocatechin gallate. Hong Kong Med J 7 (2001) 369-374
40. Paschka A.G., Butler R., and Young C.Y. Induction of apoptosis in prostate cancer cell lines by green tea component epigallocatechin-3-gallate. Cancer Lett 130 (1998) 1
41. Platz E.A., Kawachi I., Rimm E.B., et al. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow up study. J Urol 163 (2000) 490-495
42. Gann P.H., Hennekens C., Longcope C., et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 26 (1995) 40-49
43. Crispo A., Talamini R., Gallus S., et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology 64 (2004) 717-722
44. Emanuele M.A., and Emanuele N. Alcohol and the male reproductive system. Alcohol Res Health 25 (2001) 282-287
45. Gass R. Benign prostatic hyperplasia: the opposite effect of alcohol and coffee intake. BJU Int 90 (2002) 649-654
46. Harris A., Gray M.A., Slaney D.P., et al. Ethnic differences in diet and associations with clinical markers of prostate disease in New Zealand men. Anticancer Res 24 (2004) 2551-2556
47. Kang D., Andriole G.L., VanDeVooren R.C., et al. Risk behaviours and benign prostatic hyperplasia. BJU Int 93 (2004) 1241-1245
48. Morrison A.S. Risk factors for surgery of prostatic hypertrophy. Am J Epidemiol 135 (1992) 974-980
49. Moyad M.A. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs 24 (2004) 49-52
50. Crescioli C., Ferruzzi P., Caporali A., et al. Inhibition of prostate cell growth by BXL628, a calcitriol analogue selected for phase II clinical trial in patients with benign prostatic hyperplasia. Eur J Endocrinol 150 (2004) 591-603